Therapeutic strategies against tardive dyskinesia. Two decades of experience
- PMID: 6131655
- DOI: 10.1001/archpsyc.1982.04290070037008
Therapeutic strategies against tardive dyskinesia. Two decades of experience
Abstract
We reviewed 285 treatment studies involving more than 3,000 patients with neuroleptic-induced tardive dyskinesia (TD). Neuroleptic withdrawal is found to reverse dyskinesia in about 37% of patients. There is no satisfactory treatment for persistent TD. Although neuroleptics are significantly superior to most other methods of treatment in suppressing signs of dyskinesia, the safety of their long-term use in dyskinetic patients remains to be demonstrated. Putative gamma-aminobutyric acid (GABA)-ergic drugs and noradrenergic blockers deserve careful study. A strategy for determining biochemical and pharmacologic subtypes of TD appears promising. The value of the available cholinergic agents in the treatment of TD is uncertain. Caution is warranted in interpreting "positive" results with a number of other drugs, which might act as placebos or as nonspecific sedatives. Anticholinergic drugs are generally not recommended for treating dyskinetic patients. Current theories of the pathophysiology of TD may need revision. Drug-free periods do not seem to prevent TD. Antipsychotic drugs without neuroleptic side effects should be developed.
Similar articles
-
[Therapeutic measures in tardive dyskinesia].Fortschr Neurol Psychiatr. 1983 Jun;51(6):203-26. doi: 10.1055/s-2007-1002227. Fortschr Neurol Psychiatr. 1983. PMID: 6136457 German.
-
Cholinergic treatments for tardive dyskinesia.Mod Probl Pharmacopsychiatry. 1983;21:168-86. doi: 10.1159/000408492. Mod Probl Pharmacopsychiatry. 1983. PMID: 6140629 Review. No abstract available.
-
Cholinergic influences in tardive dyskinesia.Am J Psychiatry. 1977 Jul;134(7):769-74. doi: 10.1176/ajp.134.7.769. Am J Psychiatry. 1977. PMID: 869054 Clinical Trial.
-
Cholinergic medication for neuroleptic-induced tardive dyskinesia.Cochrane Database Syst Rev. 2002;(3):CD000207. doi: 10.1002/14651858.CD000207. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2018 Mar 19;3:CD000207. doi: 10.1002/14651858.CD000207.pub2. PMID: 12137608 Updated. Review.
-
Cholinergic medication for neuroleptic-induced tardive dyskinesia.Cochrane Database Syst Rev. 2000;(2):CD000207. doi: 10.1002/14651858.CD000207. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(3):CD000207. doi: 10.1002/14651858.CD000207. PMID: 10796324 Updated. Review.
Cited by
-
Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration.Psychopharmacology (Berl). 1988;94(3):421-7. doi: 10.1007/BF00174701. Psychopharmacology (Berl). 1988. PMID: 3128820
-
Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.Psychopharmacology (Berl). 1995 Jan;117(1):74-81. doi: 10.1007/BF02245101. Psychopharmacology (Berl). 1995. PMID: 7724705
-
Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.Psychopharmacology (Berl). 1994 Sep;116(1):79-84. doi: 10.1007/BF02244874. Psychopharmacology (Berl). 1994. PMID: 7862934
-
GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias.Psychopharmacology (Berl). 1988;94(3):298-301. doi: 10.1007/BF00174678. Psychopharmacology (Berl). 1988. PMID: 2895937
-
Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats.J Neural Transm Gen Sect. 1990;82(2):93-109. doi: 10.1007/BF01245166. J Neural Transm Gen Sect. 1990. PMID: 1977417
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
